{"url":"https://lda.senate.gov/api/v1/filings/c936edde-2d2f-4ec4-beea-519f0bdf4e5d/","filing_uuid":"c936edde-2d2f-4ec4-beea-519f0bdf4e5d","filing_type":"RR","filing_type_display":"Registration","filing_year":2021,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/c936edde-2d2f-4ec4-beea-519f0bdf4e5d/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"T.J. Petrizzo, Chairman & CEO","dt_posted":"2021-11-17T15:57:04-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"601 New Jersey Ave NW","registrant_address_2":"Suite 830","registrant_different_address":null,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":305932,"url":"https://lda.senate.gov/api/v1/registrants/305932/","house_registrant_id":38088,"name":"THE PETRIZZO GROUP, INC.","description":"Government Relations and Strategic Communications Firm","address_1":"601 New Jersey Avenue NW","address_2":"Suite 830","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"T.J. PETRIZZO","contact_telephone":"+1 202-365-4583","dt_updated":"2026-07-20T09:24:00.173382-04:00"},"client":{"id":212762,"url":"https://lda.senate.gov/api/v1/clients/212762/","client_id":1005255,"name":"IMMUNITYBIO, INC.","general_description":"Late-stage, cell therapy and immunotherapy co. focused on oncology & infectious disease","client_government_entity":false,"client_self_select":null,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2021-10-15"},"lobbying_activities":[{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"New Technologies for Accessible, Durable, and Broadly Protective 2nd Generation Coronavirus Vaccines","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":3241,"prefix":null,"prefix_display":null,"first_name":"TJ","nickname":null,"middle_name":null,"last_name":"PETRIZZO","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[]},{"general_issue_code":"SCI","general_issue_code_display":"Science/Technology","description":"New Technologies for Accessible, Durable, and Broadly Protective 2nd Generation Coronavirus Vaccines","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":3241,"prefix":null,"prefix_display":null,"first_name":"TJ","nickname":null,"middle_name":null,"last_name":"PETRIZZO","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"New Technologies for Accessible, Durable, and Broadly Protective 2nd Generation Coronavirus Vaccines","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":3241,"prefix":null,"prefix_display":null,"first_name":"TJ","nickname":null,"middle_name":null,"last_name":"PETRIZZO","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}